Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  adenocarcinoma of the stomach
Stage/Subtype:  adenocarcinoma of the stomach
Country:  U.S.A.
Trial Type:  Treatment
Results 1-24 of 24 for your search:
Start Over
Proton Beam Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Esophageal Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 2011-1036, NCI-2012-00078, NCT01512589
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BO27952, NCI-2013-00507, 2012-000660-22, NCT01641939
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
Afatinib Dimaleate and Trastuzumab in Treating Patients with Refractory Metastatic Esophagus or Stomach Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-166, NCI-2012-00414, NCT01522768
Biomarkers in Predicting Response to Docetaxel, Cisplatin, and Fluorouracil in Patients With Metastatic Esophagus, Gastroesophageal Junction, or Stomach Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 80
Trial IDs: J1248/ NA_00073720, NCI-2013-00058, J1248, NCT01715233
MatriStem Surgical Matrix PSM in Reducing Complications in Patients with Stomach or Esophageal Cancer Undergoing Surgery
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 13-178, NCI-2013-02006, NCT01970306
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C26002, NCI-2014-01745, 2014-000804-88, REec-2014-1176, U1111-1155-9023, NCT02202759
Nintedanib in Treating Patients with Advanced Esophageal, Gastroesophageal Junction, or Stomach Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-094, NCI-2014-01964, NCT02234596
Afatinib and Paclitaxel in Treating Patients with HER2-Positive Recurrent Advanced Gastric, Gastroesophageal Junction, or Esophageal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAM5905, NCI-2015-00758, 1200.203, NCI-2014-02350, NCT02274012
Personalized Therapy Using Genetic Markers in Treating Patients with Esophagogastric Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201412051, NCI-2014-02550, NCT02296671
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-059, NCI-2015-00402, 2014-003574-16, NCT02335411
A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 115717, NCI-2012-01219, NCT01458067
Vaccine Therapy in Treating Patients with Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor 2 Positive Cancers
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00034612, NCI-2013-00525, NCT01526473
Combination Chemotherapy in Treating Patients With Previously Untreated Locally Advanced or Metastatic Gastrointestinal Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0033, NCI-2012-00585, 12-0033-AM010, NCT01643499
Safety and Tolerability Study in Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: GS-US-296-0101, NCI-2013-01417, NCT01803282
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA224-020, NCI-2014-00315, 2014-002605-38, NCT01968109
Selinexor and Irinotecan Hydrochloride in Treating Patients with Stomach or Distal Esophageal Cancer That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17919, NCI-2014-02530, 14.11.0001, MCC 17919, NCT02283359
Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA014-001, NCI-2015-00318, FS10214100, NCT02286219
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients with Locally Advanced Gastroesophageal or Stomach Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0594, NCI-2014-02574, NCT02366819
Start Over